Stock comparison
AbbVie Inc. is 20.8x more valuable than Royalty Pharma plc by market capitalization ($440.14 B vs $21.16 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 20.8x more valuable than Royalty Pharma plc by market capitalization ($440.14 B vs $21.16 B).
Market value leader
ABBV
AbbVie Inc. is 20.8x more valuable than Royalty Pharma plc by market capitalization ($440.14 B vs $21.16 B).
Revenue leader
ABBV
RPRX: $2.38B vs ABBV: $61.16B.
Profit leader
ABBV
RPRX: $770.95M vs ABBV: $4.23B.
Margin leader
RPRX
RPRX: 32.4% vs ABBV: 6.9% net margin.
| Metric | RPRX | ABBV |
|---|---|---|
| Market cap | $21.16 B | $440.14 B |
| US-listed rank | #608 | #25 |
| Revenue (latest FY) | $2.38B | $61.16B |
| Net income (latest FY) | $770.95M | $4.23B |
| Net margin | 32.4% | 6.9% |
| P/E (trailing FY) | 27.4x | 104.2x |
| SEC filings | 588 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 20.8x more valuable than Royalty Pharma plc by market capitalization ($440.14 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while AbbVie Inc. reported $61.16B.
Full pages: Royalty Pharma plc and AbbVie Inc., or browse the full rankings.